Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

(1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different...

Descripción completa

Detalles Bibliográficos
Autores: Riestra, Sabino, Taxonera, Carlos, Zabana Abdo, Yamile, Carpio, Daniel, Chaparro, María, Barrio, Jesús, Rivero, Montserrat, López Sanroman, Antonio, Esteve, Maria, Francisco, Ruth de, Bastida, Guillermo, García López, Santiago, Mañosa, Míriam, Martin Arranz, María Dolores, Pérez Calle, José Lázaro, Guardiola, Jordi, Muñoz, Fernando, Arranz, Laura, Cabriada, José Luis, García Sepulcre, Mariana Fe, Navarro, Mercè, Montoro Huguet, Miguel Ángel, Ricart, Elena, Bermejo, Fernando, Calvet, Xavier, Piqueras, Marta, Garcia Planella, Esther, Márquez, Lucía, Mínguez, Miguel, Van Domselar, Manuel, Bujanda, Luis, Aldeguer, Xavier, Sicilia, Beatriz, Iglesias, Eva, Alcaín, Guillermo, Pérez Martínez, Isabel, Rolle, Valeria, Castaño García, Andrés, Gisbert, Javier P., Domènech, Eugeni, The ENEIDA Registry From GETECCU
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/188631
Acceso en línea:https://hdl.handle.net/2445/188631
Access Level:acceso abierto
Palabra clave:Malalties inflamatòries intestinals
Tuberculosi
Inflammatory bowel diseases
Tuberculosis
id ES_c6609f3a3841b62cf97baf4cedf508ee
oai_identifier_str oai:diposit.ub.edu:2445/188631
network_acronym_str ES
network_name_str España
repository_id_str
spelling Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCURiestra, SabinoTaxonera, CarlosZabana Abdo, YamileCarpio, DanielChaparro, MaríaBarrio, JesúsRivero, MontserratLópez Sanroman, AntonioEsteve, MariaFrancisco, Ruth deBastida, GuillermoGarcía López, SantiagoMañosa, MíriamMartin Arranz, María DoloresPérez Calle, José LázaroGuardiola, JordiMuñoz, FernandoArranz, LauraCabriada, José LuisGarcía Sepulcre, Mariana FeNavarro, MercèMontoro Huguet, Miguel ÁngelRicart, ElenaBermejo, FernandoCalvet, XavierPiqueras, MartaGarcia Planella, EstherMárquez, LucíaMínguez, MiguelVan Domselar, ManuelBujanda, LuisAldeguer, XavierSicilia, BeatrizIglesias, EvaAlcaín, GuillermoPérez Martínez, IsabelRolle, ValeriaCastaño García, AndrésGisbert, Javier P.Domènech, EugeniThe ENEIDA Registry From GETECCUMalalties inflamatòries intestinalsTuberculosiInflammatory bowel diseasesTuberculosis(1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-gamma-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18-20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50-0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66-0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20-22%] vs. 14% [95% CI 13-16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM.MDPI AG2022info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/2445/188631Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.3390/jcm11133915Journal of Clinical Medicine, 2022, vol. 11, num. 13, p. 3915https://doi.org/10.3390/jcm11133915cc by (c) Riestra, Sabino et al., 2022http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1886312026-05-27T06:46:51Z
dc.title.none.fl_str_mv Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
spellingShingle Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
Riestra, Sabino
Malalties inflamatòries intestinals
Tuberculosi
Inflammatory bowel diseases
Tuberculosis
title_short Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_full Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_fullStr Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_full_unstemmed Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
title_sort Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
dc.creator.none.fl_str_mv Riestra, Sabino
Taxonera, Carlos
Zabana Abdo, Yamile
Carpio, Daniel
Chaparro, María
Barrio, Jesús
Rivero, Montserrat
López Sanroman, Antonio
Esteve, Maria
Francisco, Ruth de
Bastida, Guillermo
García López, Santiago
Mañosa, Míriam
Martin Arranz, María Dolores
Pérez Calle, José Lázaro
Guardiola, Jordi
Muñoz, Fernando
Arranz, Laura
Cabriada, José Luis
García Sepulcre, Mariana Fe
Navarro, Mercè
Montoro Huguet, Miguel Ángel
Ricart, Elena
Bermejo, Fernando
Calvet, Xavier
Piqueras, Marta
Garcia Planella, Esther
Márquez, Lucía
Mínguez, Miguel
Van Domselar, Manuel
Bujanda, Luis
Aldeguer, Xavier
Sicilia, Beatriz
Iglesias, Eva
Alcaín, Guillermo
Pérez Martínez, Isabel
Rolle, Valeria
Castaño García, Andrés
Gisbert, Javier P.
Domènech, Eugeni
The ENEIDA Registry From GETECCU
author Riestra, Sabino
author_facet Riestra, Sabino
Taxonera, Carlos
Zabana Abdo, Yamile
Carpio, Daniel
Chaparro, María
Barrio, Jesús
Rivero, Montserrat
López Sanroman, Antonio
Esteve, Maria
Francisco, Ruth de
Bastida, Guillermo
García López, Santiago
Mañosa, Míriam
Martin Arranz, María Dolores
Pérez Calle, José Lázaro
Guardiola, Jordi
Muñoz, Fernando
Arranz, Laura
Cabriada, José Luis
García Sepulcre, Mariana Fe
Navarro, Mercè
Montoro Huguet, Miguel Ángel
Ricart, Elena
Bermejo, Fernando
Calvet, Xavier
Piqueras, Marta
Garcia Planella, Esther
Márquez, Lucía
Mínguez, Miguel
Van Domselar, Manuel
Bujanda, Luis
Aldeguer, Xavier
Sicilia, Beatriz
Iglesias, Eva
Alcaín, Guillermo
Pérez Martínez, Isabel
Rolle, Valeria
Castaño García, Andrés
Gisbert, Javier P.
Domènech, Eugeni
The ENEIDA Registry From GETECCU
author_role author
author2 Taxonera, Carlos
Zabana Abdo, Yamile
Carpio, Daniel
Chaparro, María
Barrio, Jesús
Rivero, Montserrat
López Sanroman, Antonio
Esteve, Maria
Francisco, Ruth de
Bastida, Guillermo
García López, Santiago
Mañosa, Míriam
Martin Arranz, María Dolores
Pérez Calle, José Lázaro
Guardiola, Jordi
Muñoz, Fernando
Arranz, Laura
Cabriada, José Luis
García Sepulcre, Mariana Fe
Navarro, Mercè
Montoro Huguet, Miguel Ángel
Ricart, Elena
Bermejo, Fernando
Calvet, Xavier
Piqueras, Marta
Garcia Planella, Esther
Márquez, Lucía
Mínguez, Miguel
Van Domselar, Manuel
Bujanda, Luis
Aldeguer, Xavier
Sicilia, Beatriz
Iglesias, Eva
Alcaín, Guillermo
Pérez Martínez, Isabel
Rolle, Valeria
Castaño García, Andrés
Gisbert, Javier P.
Domènech, Eugeni
The ENEIDA Registry From GETECCU
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties inflamatòries intestinals
Tuberculosi
Inflammatory bowel diseases
Tuberculosis
topic Malalties inflamatòries intestinals
Tuberculosi
Inflammatory bowel diseases
Tuberculosis
description (1) Aims: Patients receiving antitumor necrosis factor (anti-TNF) therapy are at risk of developing tuberculosis (TB), usually due to the reactivation of a latent TB infection (LTBI). LTBI screening and treatment decreases the risk of TB. This study evaluated the diagnostic performance of different LTBI screening strategies in patients with inflammatory bowel disease (IBD). (2) Methods: Patients in the Spanish ENEIDA registry with IBD screened for LTBI between January 2003 and January 2018 were included. The diagnostic yield of different strategies (dual screening with tuberculin skin test [TST] and interferon-gamma-release assay [IGRA], two-step TST, and early screening performed at least 12 months before starting biological treatment) was analyzed. (3) Results: Out of 7594 screened patients, 1445 (19%; 95% CI 18-20%) had LTBI. Immunomodulator (IMM) treatment at screening decreased the probability of detecting LTBI (20% vs. 17%, p = 0.001). Regarding screening strategies, LTBI was more frequently diagnosed by dual screening than by a single screening strategy (IGRA, OR 0.60; 95% CI 0.50-0.73, p < 0.001; TST, OR 0.76; 95% CI 0.66-0.88, p < 0.001). Two-step TST increased the diagnostic yield of a single TST by 24%. More cases of LTBI were diagnosed by early screening than by routine screening before starting anti-TNF agents (21% [95% CI 20-22%] vs. 14% [95% CI 13-16%], p < 0.001). The highest diagnostic performance for LTBI (29%) was obtained by combining early and TST/IGRA dual screening strategies in patients without IMM. (4): Conclusions: Both early screening and TST/IGRA dual screening strategies significantly increased diagnostic performance for LTBI in patients with IBD, with optimal performance achieved when they are used together in the absence of IMM.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/188631
url https://hdl.handle.net/2445/188631
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.3390/jcm11133915
Journal of Clinical Medicine, 2022, vol. 11, num. 13, p. 3915
https://doi.org/10.3390/jcm11133915
dc.rights.none.fl_str_mv cc by (c) Riestra, Sabino et al., 2022
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Riestra, Sabino et al., 2022
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI AG
publisher.none.fl_str_mv MDPI AG
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419068275032064
score 15.301603